 | Up a level |
2022
Schneeweiss, Andreas, Michel, Laura L., Moebus, Volker, Tesch, Hans, Klare, Peter, Hahnen, Eric, Denkert, Carsten, Kast, Karin, Pohl-Rescigno, Esther, Hanusch, Claus, Link, Theresa, Untch, Michael, Jackisch, Christian, Blohmer, Jens-Uwe 
ORCID: 0000-0002-7969-250X, Fasching, Peter A., Solbach, Christine, Schmutzler, Rita K., Huober, Jens, Rhiem, Kerstin, Nekljudova, Valentina, Luebbe, Kristina and Loibl, Sibylle
(2022).
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Eur. J. Cancer, 160.
S. 100 - 112.
OXFORD:
ELSEVIER SCI LTD.
ISSN 1879-0852